A Swiss-German consortium led by Volker Thiel of the Institute of Virology and Immunology and the University of Bern has partnered with Swiss startup RocketVax to develop two live attenuated intranasal vaccine candidates against SARS-CoV-2 for planned Phase 1 trials. The consortium, which also includes researchers from the University of Geneva, the Freie Universität Berlin, [...]
